Problems in the design of anticancer agents

M. D'Incalci, G. Balconi, M. Broggini, T. Colombo, M. Marzola, F. Morali, Y. Pang, S. Sen, L. Spinelli

Research output: Contribution to journalArticlepeer-review


Theoretically, two predominant paths for obtaining more selective anticancer agents may be envisaged. These are: (a) to make compounds which distribute only or preferentially in cancer cells; (b) to make compounds that are able selectively to kill or to differentiate cancer cells. Although in the last two decades research into new anticancer drugs has not produced satisfactory results, there is solid ground on which novel strategies can be developed, mainly based on a much greater biological knowledge of human tumours. This article does not review all the possible approaches that may be followed, but simply discusses some ideas and problems mainly taken from the current research of our laboratory.

Original languageEnglish
Pages (from-to)535-555
Number of pages21
JournalCancer Surveys
Issue number3
Publication statusPublished - 1989


  • antineoplastic drugs
  • distribution
  • DNA as a target of antitumour drugs
  • human cancer cells
  • immunoconjugates
  • immunotoxins

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Problems in the design of anticancer agents'. Together they form a unique fingerprint.

Cite this